One of the key non-genomic actions of estrogen is the activation of second messenger systems, such as cyclic AMP (cAMP), protein kinase A (PKA), and phosphatidylinositol-3-kinase (PI3K) [72,74]
HGF/c-Met signaling is a well-established oncogenic pathway: c-Met is amplified or overexpressed in multiple cancers (gastric, lung, renal, hepatocellular) HGF/c-Met activation promotes tumor cell proliferation, survival, invasion, and metastasis c-Met inhibitors are FDA-approved cancer drugs (cabozantinib, crizotinib, capmatinib) A compound that potentiates HGF/c-Met signaling raises theoretical concerns about promoting tumor growth or transformation with chronic use
TB-500 (Thymosin Beta-4 Fragment) Cellular-Migration & Tissue-Maintenance Research TB-500 is commonly researched for its interaction with: Cellular-migration and tissue-repair signaling Soft-tissue and connective-tissue pathways Recovery-focused regenerative mechanisms Mobility- and flexibility-related pathways Physiological-resilience and tissue-maintenance research Research involving TB-500 commonly investigates its potential interaction with connective-tissue pathways, tissue-remodeling pathways, angiogenesis-related signaling, and recovery-focused physiological mechanisms
& Rhodes, D
Zero sugar
